- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:18 | MapLight Therapeutics debuts on Nasdaq at $19, above $17 IPO price | 1 | Investing.com | ||
| 13:25 | CNS disorder biotech MapLight Therapeutics prices IPO at $17, as expected | 1 | Renaissance Capital | ||
| 12:48 | MapLight Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12:26 | MapLight goes public via $250M IPO to fund Cobenfy competitor | 1 | FierceBiotech | ||
| MAPLIGHT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03:24 | MapLight Therapeutics Prices IPO Of 14.75 Mln Shares At $17.00/shr | 342 | AFX News | WASHINGTON (dpa-AFX) - MapLight Therapeutics Inc., a clinical-stage biopharmaceutical company focused on
improving the lives of patients suffering from debilitating central nervous
system... ► Artikel lesen | |
| So | MapLight Therapeutics, Inc.: MapLight Therapeutics Announces Pricing of Initial Public Offering | 70 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating... ► Artikel lesen | |
| Fr | MapLight Therapeutics, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 20.10. | MapLight Therapeutics IPO reportedly well oversubscribed | 4 | Investing.com | ||
| 08.10. | MapLight's $251m IPO sees schizophrenia drug developers on top | 2 | Pharmaceutical Technology | ||
| 07.10. | Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO | 34 | Seeking Alpha | ||
| 07.10. | MapLight uses workaround to tee up IPO during government shutdown | 1 | BioPharma Dive | ||
| 07.10. | MapLight illuminates $262M IPO plans to fund Cobenfy competitor | 1 | FierceBiotech | ||
| 06.10. | CNS disorder biotech MapLight Therapeutics sets terms for $251 million IPO | 1 | Renaissance Capital | ||
| 06.10. | MapLight Therapeutics files for 14.75M share IPO at $17/sh | 2 | Investing.com | ||
| 06.10. | MapLight Therapeutics, Inc. - S-1/A, General form for registration of securities | 3 | SEC Filings | ||
| 22.09. | Big Pharma-backed MapLight plots IPO to advance neuro pipeline | 3 | FierceBiotech | ||
| 22.09. | MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug | 5 | BioPharma Dive | ||
| 19.09. | CNS disorder biotech MapLight Therapeutics files for a $100 million IPO | 2 | Renaissance Capital | ||
| 19.09. | MapLight files for proposed Nasdaq IPO | 1 | Investing.com | ||
| 19.09. | MapLight Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,99 | +42,40 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| QIAGEN | 41,860 | -1,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| EVOTEC | 7,124 | +2,18 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,170 | +41,10 % | Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday | ||
| RECURSION PHARMACEUTICALS | 6,435 | +6,54 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| NUVALENT | 99,55 | +6,60 % | Piper Sandler erhöht Kursziel für Nuvalent auf 128 US-Dollar wegen ALK-Potenzial | ||
| BIONTECH | 90,55 | -0,28 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,520 | -43,06 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 183,62 | +5,69 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| ZENAS BIOPHARMA | 32,490 | +35,71 % | Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis | - Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,710 | -4,44 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 57,00 | -2,56 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| COGENT BIOSCIENCES | 16,050 | +6,08 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
| TOURMALINE BIO | 47,990 | +0,04 % | Novartis Pharma AG: Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer | Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with... ► Artikel lesen | |
| IMMUNOVANT | 21,490 | +13,52 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen |
Das Unternehmen MAPLIGHT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 18,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAPLIGHT THERAPEUTICS INC finden Sie auf Wallstreet Online.